EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction
Peter Seizer1; Oliver Borst1; Harald F. Langer1; Andreas Bültmann2; Götz Münch2; Yared Herouy3; Konstantinos Stellos1; Björn Krämer1; Boris Bigalke1; Berthold Büchele4; Max G. Bachem5; Dietmar Vestweber6; Thomas Simmet4; Meinrad Gawaz1; Andreas E. May1
1Medizinische Klinik III, Eberhard Karls University Tuebingen, Tuebingen, Germany; 2Corimmun GmbH, Martinsried, Germany; 3Dermatologische Universitätsklinik Freiburg, Freiburg, Germany; 4Institute of Pharmacololgy of Natural Products and Clinical Pharmacology, Ulm University, Ulm, Germany; 5Department of Clinical Chemistry and Pathobiochemistry, University of Ulm, Ulm, Germany; 6Department of Vascular Cell Biology, Max-Planck Institute for Molecular Biomedicine, Münster, Germany
Summary
The Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147, basigin) is an immunoglobulin-like receptor expressed in various cell types. During cellular interactions homotypic EMMPRIN-EMMPRIN interactions are known to induce the synthesis of matrix metalloproteinases. Recently, we have identified EMMPRIN as a novel receptor on platelets. To our knowledge EMMPRIN has not been shown to serve as adhesion receptor, yet. Here we characterise platelet glycoprotein VI (GPVI) as a novel adhesion receptor for EMMPRIN. Human platelets were prestimulated with ADP and perfused over immobilised recombinant EMMPRIN-Fc or Fc-fragments under arterial shear conditions. ADP-stimulated platelets showed significantly enhanced rolling (but not enhanced firm adhesion) on immobilised EMMPRIN- Fc compared to Fc. Pretreatment of platelets with blocking mAbs anti-EMMPRIN or anti-GPVI leads to a significant reduction of rolling platelets on immobilised EMMPRIN-Fc, whereas pretreatment with blocking mAbs anti-p-selectin, anti- α4-integrin or anti-GPIIb/IIIa complex (20 μg/ml each) had no effect. Consistently, chinese hamster ovary (CHO) cells stably transfected with GPVI showed enhanced rolling (but not adhesion) on immobilised EMMPRIN-Fc in comparison to nontransfected CHO cells. Similarly, CHO cells stably transfected with EMMPRIN showed enhanced rolling on immobilised GPVIFc (or EMMPRIN-Fc) compared to non transfected CHO-cells. Finally, specific binding of EMMPRIN to GPVI was demonstrated by a modified ELISA and surface plasmon resonance technology with a dissociation constant of 88 nM. Platelet GPVI is a novel receptor for EMMPRIN and can mediate platelet rolling via GPVIEMMPRIN interaction. Keywords
Atherosclerosis, Platelets, EMMPRIN, GPVI
DOI
http://dx.doi.org/10.1160/TH08-06-0368